中国临床药学杂志2024，Vol.33Issue(10)：746-750,5.DOI:10.19577/j.1007-4406.2024.10.005
基于SWARA-TOPSIS法评价替考拉宁临床使用合理性
Evaluation of teicoplanin rationality pattern based on the SWARA-TOPSIS method
摘要
Abstract
AIM To evaluate the rational use of teicoplanin in clinical practice.METHODS Patients who used teicoplanin from October 2020 to December 2022 were selected as the research subjects.Based on drug instructions,guidelines,relevant literature and expert opinions,4 first-level indicators and 11 second-level evaluation indicators were subdivided.The step-wise weighted assessment ratio analysis(SWARA)method was employed to determine the weight of each evaluation indicator.The weighted techinque for order preference bysimilarity to ideal solution(TOPSIS)method was utilized to comment on cases and comprehensively evaluate the rationality of clinical use of teicoplanin.RESULTS Among the weights calculated by the SWARA method,indications,drug selection,usage and dosage,and administration route had relatively high proportions(0.273,0.188,and 0.139).Among the 100 cases commented on by the weighted TOPSIS method,35 cases(35.00％)were reasonable in use,29 cases(29.00％)were basically reasonable in use,and 36 cases(36.00％)were unreasonable in use.CONCLUSION A combined method of SWARA and TOPSIS is employed to conduct a comprehensive evaluation of the clinical use of teicoplanin.It reflects that there are still certain problems in the clinical use process.Therefore,further management should be strengthened to promote its rational and correct use.关键词
替考拉宁/逐步加权评估分析比率法/逼近理想解排序法/合理用药Key words
teicoplanin/stepwise weight assessment ratio analysis/techinque for order preference by similarity to ideal solution/rational use of drug引用本文复制引用
黄磊,张琳琳,王红霞,吴慧,胡晔,尹存林..基于SWARA-TOPSIS法评价替考拉宁临床使用合理性[J].中国临床药学杂志,2024,33(10):746-750,5.基金项目
江苏省药学会-天晴医院药学科研项目(编号Q202153) （编号Q202153）
